CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Index investing offers a straightforward path to retirement goals with broad market exposure and low costs. This intro explains why it often suits long-term planning and how to begin with simple steps.
21,933 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Wearables deliver a flood of personal-health data, but turning that data into real-life action remains a hurdle as st...
Two software leaders battle for your 2026 portfolio: Duolingo and Zeta Global. This guide compares business models, g...
Bitwise’s Matt Hougan argues that Strategy’s role as Bitcoin’s dominant corporate buyer is shifting as institutions s...
Private AI leaders OpenAI and Anthropic see valuations near $1 trillion as investors chase growth. A cooling IPO wind...
Federal agencies are deploying Anthropic’s Mythos to hunt bugs in critical code, a move that broadens AI’s role in na...
The question rivian stock: dip? is less about a single price move and more about the broader EV tide. This guide brea...
JPMorgan says it has built an AI agent to gauge markets and economics with the aim of outperforming the standard 60/4...
General Dynamics posted a strong first quarter, while Lockheed Martin unveiled a major Ultra Maritime purchase, sharp...
AI-driven capex is lifting lithography demand, placing ASML at the center of a multiyear upgrade cycle. This piece ex...
Amazon enters the back half of 2026 with sustained AWS growth, a scaling silicon stack, and a resilient Prime-driven ...
Southwest Airlines is rolling out tweaks to its newly adopted boarding plan after reports of crowded storage spaces a...